Emerging and future therapies for Allergic rhinitis

A. Licari, A. Marseglia, S. Caimmi, A. Ricci, B. Rundo, D. Poddighe, G. L. Marseglia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30% of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.

Original languageEnglish
Pages (from-to)38-46
Number of pages9
JournalJournal of Biological Regulators and Homeostatic Agents
Volume29
Issue number2
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Immunologic Desensitization
Therapeutics
Allergens
Comorbidity
Asthma
Guidelines
Drug Therapy
Allergic Rhinitis
Population
Global Health

Keywords

  • Allergic rhinitis
  • Immunotherapy
  • Omalizumab
  • Pharmacotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Licari, A., Marseglia, A., Caimmi, S., Ricci, A., Rundo, B., Poddighe, D., & Marseglia, G. L. (2015). Emerging and future therapies for Allergic rhinitis. Journal of Biological Regulators and Homeostatic Agents, 29(2), 38-46.

Emerging and future therapies for Allergic rhinitis. / Licari, A.; Marseglia, A.; Caimmi, S.; Ricci, A.; Rundo, B.; Poddighe, D.; Marseglia, G. L.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 29, No. 2, 01.01.2015, p. 38-46.

Research output: Contribution to journalArticle

Licari, A, Marseglia, A, Caimmi, S, Ricci, A, Rundo, B, Poddighe, D & Marseglia, GL 2015, 'Emerging and future therapies for Allergic rhinitis', Journal of Biological Regulators and Homeostatic Agents, vol. 29, no. 2, pp. 38-46.
Licari A, Marseglia A, Caimmi S, Ricci A, Rundo B, Poddighe D et al. Emerging and future therapies for Allergic rhinitis. Journal of Biological Regulators and Homeostatic Agents. 2015 Jan 1;29(2):38-46.
Licari, A. ; Marseglia, A. ; Caimmi, S. ; Ricci, A. ; Rundo, B. ; Poddighe, D. ; Marseglia, G. L. / Emerging and future therapies for Allergic rhinitis. In: Journal of Biological Regulators and Homeostatic Agents. 2015 ; Vol. 29, No. 2. pp. 38-46.
@article{805b2ed519254a25a08ea37ecad35a63,
title = "Emerging and future therapies for Allergic rhinitis",
abstract = "Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30{\%} of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.",
keywords = "Allergic rhinitis, Immunotherapy, Omalizumab, Pharmacotherapy",
author = "A. Licari and A. Marseglia and S. Caimmi and A. Ricci and B. Rundo and D. Poddighe and Marseglia, {G. L.}",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "29",
pages = "38--46",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife SAS",
number = "2",

}

TY - JOUR

T1 - Emerging and future therapies for Allergic rhinitis

AU - Licari, A.

AU - Marseglia, A.

AU - Caimmi, S.

AU - Ricci, A.

AU - Rundo, B.

AU - Poddighe, D.

AU - Marseglia, G. L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30% of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.

AB - Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30% of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.

KW - Allergic rhinitis

KW - Immunotherapy

KW - Omalizumab

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84985942561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985942561&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 38

EP - 46

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -